In the wake of research suggesting a skin-cancer drug may have benefits in treating Alzheimer’s disease, physicians and advocacy groups are getting a flurry of calls from patients seeking to use the drug off-label. Keith Flaherty, HMS associate professor of medicine at Massachusetts General Hospital, and Reisa Sperling, HMS associate professor of neurology at Brigham and Women’s Hospital, are quoted.
